NeuroVive Pharmaceutical AB

https://www.neurovive.com

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive's products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive's research programs also include products for the treatment of brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive's shares are listed on NASDAQ OMX, Stockholm, Sweden. Current status of NeuroVive's products CicloMulsion® NeuroVive's product CicloMulsion® is the first cyclophilin inhibitor developed for the treatment of reperfusion injury. The product's potential in the treatment of myocardial infarction is currently being evaluated in a clinical phase III study. The last of a total of 972 patients was enrolled on 16 February 2014. The results of the study are due to be announced in 2015 following the completion of the one-year follow-up of all patients and the analysis of the study data. NeuroSTAT® NeuroVive is developing NeuroSTAT® for the treatment of patients with moderate or severe traumatic brain injury. NeuroSTAT® is currently being evaluated in a clinical phase IIa study at Copenhagen University Hospital. The study focuses on safety and pharmacokinetics, and 7 of 20 planned patients have been enrolled so far. A phase III study is currently being planned and designed. NeuroVive has secured orphan drug designation for NeuroSTAT® for moderate and severe traumatic brain injury in the US and EU, which implies market exclusivity for seven years in the US and ten years in the EU, from the date NeuroVive obtains market authorization. NVP018 NVP018 is NeuroVive's primary drug candidate in the company's new portfolio of potent cyclophilin inhibitors belonging to a family of molecules known as Sangamides. Sangamides are analogs of the naturally-occurring polyketide Sanglifehrin A and are derived from a new and unique polyketide engineering technology. NVP018 has undergone extensive pre-clinical development for the treatment of chronic Hepatitis B and C and is outlicensed to OnCore Biopharma for further development and commercialization for the treatment of chronic Hepatitis B. The product has demonstrated high potency against virus replication and has a positive safety and pharmacokinetic profile. Cyclophilin inhibitors potentially have a wide range of applications. NVP019 NVP019 is based on the same active substance as NVP018 and is being developed as the next generation cyclophilin inhibitor for acute heart and nerve cell damage, but also for other acute heart conditions and acute conditions where general protection of vital organs is central to the progression of the disease. An intravenous formulation will be evaluated for this purpose in collaboration with external parties such as Hospices Civils de Lyon within the framework of the OPeRa program. Other products More information about all products developed by NeuroVive can be found at http://www.neurovive.se/index.php/en/research-development/research-overview *

	Start	2013-11-18 existent
	Group	NeuroVive (Group)
	Industry	pharmaceutical
	Person	Brönnegård, Mikael (NeuroVive 201409 CEO)

	Region	Lund
	Country	Sweden
	Street	2 Scheelevägen Medicon Village
	City	22381 Lund
	Tel	+46-46-275-6220
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	SEK
	Annual sales	8,333,000 (income, total (2014) 2014-12-31)
	Profit	-44,673,000 (2014-12-31)
	Cash	49,698,000 (2014-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)